

V-CLAMP

Product Introduction

Transapical approach



Transapical implantation. The catheter manipulation time is about 20 minutes. Shorter operative time, lower operative risk.

Minimal invasive surgery



Cardiopulmonary bypass is not required. Less trauma and complication. Rapid post-operative recovery.

Precisely capture leaflet



Smaller-sized delivery system (14F). Different size of devices can be provided for different mitral annular size and MR pattern. Multiple clips can be implanted for reducing residual MR.

Echo-guided Image



Procedural guiding of the V-clamp implantation with 2D and 3D transesophageal echocardiography (TEE). X-ray fluoroscopy is not necessary.



TREATMENT OF PET CARDIAC DISEASE

Leading canine mitral valve interventional device with proven safety and effectiveness in the world



Website : www.hongyumedtechglobal.com

Address : Building 1, No. 3699 Yuanjiang Road,
Minhang District, Shanghai

Email : customer_service@hongyumedtech.com



instagram



wechat

V-CLAMP



INTRODUCTION

Based on the transcatheter edge-to-edge mitral valve repair, mitral valve clamping system has been widely used in human and proved to be safe and effective. Through the minimally invasive method on the body surface, a clamp is implanted through the apex of the pet dog. After clamping, the valve is in the shape of a double hole, which reduces the area of regurgitation and achieves the therapeutic effect.

V-Clamp is proved to effectively reduce severity of canine mitral valve regurgitation, and the operation is performed through a small apical incision, which greatly improves the safety of the operation.

Company Profile



Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicating to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the self-developed mitral valve Interventional repair device V-CLAMP.

It is the leading surgical instrument around the world which can be used to treat mitral regurgitation for pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.

V-CLAMP devices have successfully launched in hospitals and institutions from home and abroad.

GLOBAL FOOTPRINT

Hongyu medical is currently cooperating with many top universities and scientific research institutions in the field of pet therapy in the world.



Related Study



RESEARCH REPORT
published: 17 December 2020
doi: 10.3389/fvets.2020.587679



Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs

Bo Liu¹, Stacey B. Leach², Wenshi Pan³, Fangyu Zheng⁴, Lijun Jia⁵, Xueying Zhou⁶ and Jing Li^{1*}

¹College of Veterinary Medicine, China Agricultural University, Beijing, China, ²Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States, ³Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China, ⁴Shanghai Key Laboratory of Pre-Clinical Research and Evaluation for Cardiovascular Medical Devices, Fudan University National Cardiovascular Center, Fudan University Medical College and Chinese Academy of Medical Sciences, Beijing, China

Background: Veterinary management of mitral valve regurgitation due to myxomatous valve disease in dogs is limited to medical treatments, which only postpones the onset of congestive heart failure or alleviates clinical symptoms. Most surgical procedures to manage this condition in humans require cardiopulmonary bypass and have a high risk of complications.

Animals: Eight dogs with naturally occurring mitral valve regurgitation.

Methods: Prospective observational study. All dogs were treated with a novel edge-to-edge transcatheter device named ValveClamp. The total surgical procedural time and total catheterization time were recorded. Echocardiographic variables measured pre- and post-procedure were compared using Wilcoxon signed-rank test with a $P < 0.05$ considered significant. Data were expressed as median and interquartile range and absolute numbers and percentages.

Results: The procedural success rate was 100% and all the dogs survived without complications. The median (interquartile range) total surgical procedural time was 86.5 (76–96.2) minutes and catheterization time was 23.5 (22–33.8) minutes. Echocardiography revealed a significant reduction in mitral regurgitation severity in all dogs following the procedure based on both a reduced mitral regurgitant maximum jet area ($P = 0.012$) and a reduced mitral regurgitant maximum jet area to left atrial area ($P = 0.018$).

Conclusion: The ValveClamp device is effective at reducing the severity of mitral regurgitation in dogs with naturally occurring myxomatous valve disease.

Keywords: canine, mitral valve, myxomatous degeneration, transcatheter, valve surgery

INTRODUCTION

Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs, primarily affecting small breeds (1). The standard care for this disease is primarily medical therapy, while surgical treatment is performed in a minority of dogs (2). Medical therapy postpones the onset of congestive heart failure (CHF), and also increases the survival time since CHF develops.

Frontiers in Veterinary Science | www.frontiersin.org

December 2020 | Volume 7 | Article 587679

More cases



Age: 11
Weight: 7.3KG
MMVD: B2



Age: 10
Weight: 9.1KG
MMVD: C



Age: 12
Weight: 10KG
MMVD: C



Age: 9
Weight: 4KG
MMVD: C



Age: 12
Weight: 3.2KG
MMVD: C



Age: 9
Weight: 5KG
MMVD: D